These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 26350300

  • 1. Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, is Reduced by a Monoclonal Antibody to Marinobufagenin.
    Grigorova YN, Juhasz O, Zernetkina V, Fishbein KW, Lakatta EG, Fedorova OV, Bagrov AY.
    Am J Hypertens; 2016 May; 29(5):641-6. PubMed ID: 26350300
    [Abstract] [Full Text] [Related]

  • 2. Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats.
    Fedorova OV, Fadeev AV, Grigorova YN, Marshall CA, Zernetkina V, Kolodkin NI, Agalakova NI, Konradi AO, Lakatta EG, Bagrov AY.
    J Cardiovasc Pharmacol; 2019 Nov; 74(5):436-442. PubMed ID: 31415452
    [Abstract] [Full Text] [Related]

  • 3. Dietary Sodium Restriction Reduces Arterial Stiffness, Vascular TGF-β-Dependent Fibrosis and Marinobufagenin in Young Normotensive Rats.
    Grigorova YN, Wei W, Petrashevskaya N, Zernetkina V, Juhasz O, Fenner R, Gilbert C, Lakatta EG, Shapiro JI, Bagrov AY, Fedorova OV.
    Int J Mol Sci; 2018 Oct 15; 19(10):. PubMed ID: 30326586
    [Abstract] [Full Text] [Related]

  • 4. Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
    Fedorova OV, Emelianov IV, Bagrov KA, Grigorova YN, Wei W, Juhasz O, Frolova EV, Marshall CA, Lakatta EG, Konradi AO, Bagrov AY.
    J Hypertens; 2015 Aug 15; 33(8):1602-10. PubMed ID: 26136067
    [Abstract] [Full Text] [Related]

  • 5. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension.
    Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA, Tapilskaya NI, Bzhelyansky A, Reznik VA, Frolova EV, Nikitina ER, Budny GV, Longo DL, Lakatta EG, Bagrov AY.
    J Hypertens; 2008 Dec 15; 26(12):2414-25. PubMed ID: 19008721
    [Abstract] [Full Text] [Related]

  • 6. Effect of Cardiotonic Steroid Marinobufagenin on Vascular Remodeling and Cognitive Impairment in Young Dahl-S Rats.
    Grigorova YN, Juhasz O, Long JM, Zernetkina VI, Hall ML, Wei W, Morrell CH, Petrashevskaya N, Morrow A, LaNasa KH, Bagrov AY, Rapp PR, Lakatta EG, Fedorova OV.
    Int J Mol Sci; 2022 Apr 20; 23(9):. PubMed ID: 35562955
    [Abstract] [Full Text] [Related]

  • 7. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia.
    Fedorova OV, Ishkaraeva VV, Grigorova YN, Reznik VA, Kolodkin NI, Zazerskaya IE, Zernetkina V, Agalakova NI, Tapilskaya NI, Adair CD, Lakatta EG, Bagrov AY.
    Int J Mol Sci; 2018 Aug 13; 19(8):. PubMed ID: 30104471
    [Abstract] [Full Text] [Related]

  • 8. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension.
    Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY.
    Circulation; 2002 Mar 05; 105(9):1122-7. PubMed ID: 11877366
    [Abstract] [Full Text] [Related]

  • 9. Antibody to Endogenous Cardiotonic Steroid Reverses Vascular Fibrosis and Restores Vasorelaxation in Chronic Kidney Disease.
    Agalakova NI, Mikhailova EV, Ershov IA, Nadei OV, Pyankov AA, Galagoudza MM, Adair CD, Romanova IV, Bagrov AY.
    Int J Mol Sci; 2024 Aug 15; 25(16):. PubMed ID: 39201581
    [Abstract] [Full Text] [Related]

  • 10. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
    Fedorova OV, Kolodkin NI, Agalakova NI, Lakatta EG, Bagrov AY.
    Hypertension; 2001 Feb 15; 37(2 Pt 2):462-6. PubMed ID: 11230319
    [Abstract] [Full Text] [Related]

  • 11. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
    Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY.
    Hypertension; 2003 Mar 15; 41(3):505-11. PubMed ID: 12623951
    [Abstract] [Full Text] [Related]

  • 12. Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia.
    Agalakova NI, Reznik VA, Nadei OV, Ershov IA, Rassokha OS, Vasyutina ML, Ivanov DO, Adair CD, Galagudza MM, Bagrov AY.
    Am J Hypertens; 2020 May 21; 33(6):514-519. PubMed ID: 31713584
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure.
    Haller ST, Kennedy DJ, Shidyak A, Budny GV, Malhotra D, Fedorova OV, Shapiro JI, Bagrov AY.
    Am J Hypertens; 2012 Jun 21; 25(6):690-6. PubMed ID: 22378033
    [Abstract] [Full Text] [Related]

  • 14. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells.
    Periyasamy SM, Liu J, Tanta F, Kabak B, Wakefield B, Malhotra D, Kennedy DJ, Nadoor A, Fedorova OV, Gunning W, Xie Z, Bagrov AY, Shapiro JI.
    Kidney Int; 2005 May 21; 67(5):1868-77. PubMed ID: 15840034
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal Antibody to Marinobufagenin Downregulates TGFβ Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Salt-Sensitive Hypertension.
    Zhang Y, Wei W, Shilova V, Petrashevskaya NN, Zernetkina VI, Grigorova YN, Marshall CA, Fenner RC, Lehrmann E, Wood WH, Becker KG, Lakatta EG, Bagrov AY, Fedorova OV.
    J Am Heart Assoc; 2019 Oct 15; 8(20):e012138. PubMed ID: 31576777
    [Abstract] [Full Text] [Related]

  • 16. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta.
    Fedorova OV, Agalakova NI, Morrell CH, Lakatta EG, Bagrov AY.
    Hypertension; 2006 Dec 15; 48(6):1160-8. PubMed ID: 17043158
    [Abstract] [Full Text] [Related]

  • 17. Endogenous cardiotonic steroids in chronic renal failure.
    Kolmakova EV, Haller ST, Kennedy DJ, Isachkina AN, Budny GV, Frolova EV, Piecha G, Nikitina ER, Malhotra D, Fedorova OV, Shapiro JI, Bagrov AY.
    Nephrol Dial Transplant; 2011 Sep 15; 26(9):2912-9. PubMed ID: 21292813
    [Abstract] [Full Text] [Related]

  • 18. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake.
    Fedorova OV, Kolodkin NI, Agalakova NI, Namikas AR, Bzhelyansky A, St-Louis J, Lakatta EG, Bagrov AY.
    J Hypertens; 2005 Apr 15; 23(4):835-42. PubMed ID: 15775789
    [Abstract] [Full Text] [Related]

  • 19. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.
    Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT.
    J Hypertens; 2000 Feb 15; 18(2):209-15. PubMed ID: 10694190
    [Abstract] [Full Text] [Related]

  • 20. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats.
    Fedorova OV, Lakatta EG, Bagrov AY.
    Circulation; 2000 Dec 12; 102(24):3009-14. PubMed ID: 11113054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.